Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bristol Myers Squibb Co | 150 |
| 2 | Sanofi SA | 123 |
| 3 | Pfizer Inc | 83 |
| 4 | Merck and Co Inc | 63 |
| 5 | Genfit SA | 24 |
| 6 | Abbott Laboratories | 18 |
| 7 | AbbVie Inc | 17 |
| 8 | Organon and Co | 14 |
| 9 | Lexicon Pharmaceuticals Inc | 11 |
| 10 | DSM Firmenich AG | 9 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 781 |
| 2 | C07D | Heterocyclic compounds | 591 |
| 3 | A61K | Medicinal preparations | 519 |
| 4 | C07C | Acyclic and carbocyclic compounds | 106 |
| 5 | C07H | Sugars and derivatives | 102 |
| 6 | C07F | Organometallic compounds | 66 |
| 7 | C07K | Peptides | 55 |
| 8 | C07B | General methods of organic chemistry | 43 |
| 9 | G01N | Investigating / analysing materials | 43 |
| 10 | C12Q | Measuring/testing involving enzymes | 21 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | 2011 | Ascendis Pharma AS | 179 |
| DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | 2010 | Pfizer Inc | 142 |
| FLUORINATED HETEROARYLS | 2010 | Pfizer Inc | 106 |
| BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES AS APJ RECEPTOR MODULATORS | 2014 | Sanofi SA | 78 |
| TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | 2009 | Bristol Myers Squibb Co | 90 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2019 | 3 |
| 2020 | 1 |
| 2023 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Mike Tobyn | Bristol-Myers Squibb (United Kingdom) | 6 |
| 2 | Matthew D. Hall | National Institutes of Health | 4 |
| 3 | John F. Gamble | Bristol-Myers Squibb (United Kingdom) | 3 |
| 4 | Andrew B. Dennis | Bristol-Myers Squibb (Germany) | 3 |
| 5 | Bob Stork | Solvay (Netherlands) | 2 |
| 6 | Tiny J. P. Adolfs | Solvay (Netherlands) | 2 |
| 7 | Reşat Çınar | National Institutes of Health | 2 |
| 8 | Rina Soni | Zydus Lifesciences Limited (India) | 2 |
| 9 | Andrew C. McCreary | Solvay (Netherlands) | 2 |
| 10 | Anil Kumar Misra | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Surface energy analysis as a tool to probe the surface energy characteristics of micronized materials—A comparison with inverse gas chromatography | 2011 | 88 | Chemistry and Stereochemistry Studies |
| Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity‐induced chronic kidney disease | 2019 | 73 | Cannabis and Cannabinoid Research |
| Physical stability and recrystallization kinetics of amorphous ibipinabant drug product by fourier transform raman spectroscopy | 2011 | 59 | Drug Solubulity and Delivery Systems |
| Formulation and process design for a solid dosage form containing a spray-dried amorphous dispersion of ibipinabant | 2012 | 50 | Drug Solubulity and Delivery Systems |
| Roller compaction: Application of an in-gap ribbon porosity calculation for the optimization of downstream granule flow and compactability characteristics | 2010 | 39 | Drug Solubulity and Delivery Systems |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Ibipinabant?
Which companies hold the most patents related to Ibipinabant?
What are the primary research topics associated with Ibipinabant in the academic literature?
How has patent activity around Ibipinabant trended in recent years?
What are the most common patent classification codes for Ibipinabant-related inventions?